How Long Does Spravato Take to Work? A Realistic Treatment Timeline
When you have spent months trying to feel better, waiting through another treatment can feel exhausting. How long does Spravato take to work? Some clinical studies have detected average symptom improvement within about 24 hours, but that is not a promise that you will feel different after your first visit. For treatment-resistant depression, the initial treatment phase lasts four weeks, followed by an assessment of whether continuing is appropriate.
The most useful timeline separates three questions: when an early change might appear, when your clinician will review the overall benefit, and how improvement would be maintained. A fast initial response, full remission, and lasting recovery are not the same outcome.
Start with the right treatment and indication
Spravato contains esketamine and is not interchangeable with a compounded ketamine spray or an intravenous ketamine service. The current Spravato prescribing information permits it alone or with an oral antidepressant for adult treatment-resistant depression. A separate indication for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior requires an oral antidepressant alongside it.
This article focuses on the treatment-resistant depression timeline. Do not assume that every indication, product, or treatment plan follows the same sequence. Your clinician should explain why Spravato is being considered and what the initial review will measure.
Administration takes place under clinical supervision, with at least two hours of monitoring afterward and an assessment before discharge. It is not a medicine to take home and use more frequently when progress feels slow. Never adjust the schedule or other prescribed medicines on your own.
An early change may occur, but one day is not the whole answer
In its announcement of the monotherapy approval, the manufacturer reported that the supporting trial found a difference from placebo as early as approximately 24 hours, while the main efficacy assessment occurred at four weeks. That distinction matters: the early result describes a group comparison, not a guaranteed deadline for each patient.
You may notice a change in distress or daily functioning, notice little initially, or find that different symptoms change at different times. Tell the team what you experience rather than trying to match an expected story. Feeling sedated or dissociated during the appointment is not, by itself, evidence that depression is improving.
An illustrative report might be, “Starting breakfast felt a little easier, but I still have very little interest in anything.” That is useful information without being labeled a response or remission. A clinician can consider it alongside structured assessments, adverse effects, and your wider situation.
Watch the video: How Ketamine Treats Depression (Yale Medicine)
Spravato treatment schedule: the first four weeks
For adult treatment-resistant depression, the labeled induction phase involves twice-weekly treatment during weeks one through four. Your clinician assesses benefit at the end of that phase. Completing four or eight sessions does not guarantee relief; the purpose of the review is to decide whether the actual benefit and tolerability support further care.
For context, the NIMH guide to mental health medications explains that conventional antidepressants generally take several weeks to work. The possibility of a faster onset with Spravato does not make it the best treatment for every person, and it does not eliminate the need for follow-up.
Ask what will happen if you miss a visit, develop a concerning reaction, or cannot manage the practical schedule. These are clinical planning questions, not reasons to rearrange treatment yourself. A workable plan includes communication between appointments as well as appointments on a calendar.
Track changes that matter outside the treatment room
The NIMH appointment-preparation guide encourages bringing specific concerns and medication information. A brief note can help when days blur together or concentration is limited. Choose a few relevant observations rather than monitoring yourself all day.
Record your main difficulty, any change in daily functioning, and adverse effects or concerns. Examples include preparing meals, staying with a conversation, beginning a necessary task, or experiencing interest and pleasure. Also report changes in suicidal thoughts promptly rather than saving them for a routine summary.
Keep the descriptions honest. “I attended work but felt just as distressed” is different from “Work required less effort and I could concentrate longer.” Both are useful. These notes complement clinical rating scales; they are not a home scoring system that tells you whether you qualify to continue.
Spravato maintenance: what happens after the four-week review?
For patients continuing treatment for TRD, current labeling describes weekly appointments during weeks five through eight. From week nine onward, treatment may be weekly or every two weeks, individualized to the least frequent schedule that maintains response or remission. These are labeled phases, not instructions to choose your own appointment interval.
Maintenance is a different question from initial response. Someone who improves still needs a discussion about how to sustain benefit, monitor adverse effects, and manage the practical demands of ongoing care. Feeling better does not automatically mean every treatment can be stopped immediately.
Ask when continuation will be reviewed and what would lead to changing the plan. There is no universal promise of a fixed number of maintenance visits or a lifelong course for everyone. The decision should be revisited in the context of benefit, safety, other treatments, and your circumstances.
If Spravato is not working, ask for a specific reassessment
A review of depression care should consider which symptoms have changed, which remain difficult, and whether the current diagnosis and treatment plan still fit. Needing that discussion is not a personal failure or evidence that you did not approach treatment positively enough.
Bring information about missed visits, access difficulties, other medication changes, and adverse effects. Ask whether additional assessment, a change in the wider plan, or a different intervention is appropriate. Do not continue solely because you have already invested time or money, and do not stop prescribed care independently.
A helpful question is: “What evidence of benefit are we seeing, what remains uncertain, and what is the next decision point?” That invites an accountable plan rather than either an unrealistic guarantee or an indefinite instruction to keep waiting.
Do not wait for the timeline when safety changes
Report significant worsening, troubling adverse effects, or difficulty meeting basic needs promptly. Follow the instructions your treatment team provides for symptoms after a session, and seek emergency help for severe breathing difficulty, collapse, or another life-threatening reaction.
Spravato has not been demonstrated to prevent suicide or reduce suicidal ideation or behavior, according to its labeling. It does not replace hospitalization when clinically necessary. Do not interpret a planned fast-acting treatment as permission to delay urgent assessment when you feel unsafe.
Before beginning, make sure you know which number handles routine questions, what support is available outside appointment hours, and which situations require emergency services. A responsible timeline includes a way to respond to deterioration, not just a schedule for hoped-for improvement.
Discussing a realistic plan with Sophroneo
Sophroneo Behavioral Health & TMS lists Spravato among its mental health services and also provides therapy and counseling. With locations in Powder Springs and Marietta, the practice serves the Atlanta area. Contact Sophroneo to discuss your treatment history, confirm the treatment location, and ask how progress would be reviewed. An assessment can help determine whether Spravato belongs in your plan; the timeline alone cannot establish suitability.
Frequently asked questions
Should I feel better after the first Spravato session?
Some people may notice early changes, but a first-session response is not guaranteed. Describe both symptoms and adverse effects to the team. The clinical question is how you change over the planned treatment phase, not whether you reproduce an online account after one visit.
Is no improvement after four weeks a reason to change the plan?
It is a reason for a clear clinical review. The label calls for assessing benefit at the end of induction. Your clinician should discuss the actual response, tolerability, and alternatives rather than guaranteeing that more sessions will eventually work. Do not adjust treatment independently.
Can I stop my oral antidepressant because Spravato can be used alone?
No medication change should be made on that basis alone. Monotherapy is permitted for the adult TRD indication, but a separate indication has different requirements. Your prescriber must decide how that applies to your individual treatment and explain any changes safely.
In the United States, call or text 988 for emotional crisis support or suicidal thoughts. Call 911 for immediate danger or a life-threatening emergency. Routine treatment scheduling is not emergency care.
This article is educational, not an individual prognosis, prescribing recommendation, or treatment schedule. Follow your clinician's instructions.
Comments